Jean Gutnecht
Frejus, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.
Journal: Clinical hematology international
Published: December 04, 2025
Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 25, 2020
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
Journal: Blood cancer journal
Published: March 15, 2020
Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.
Journal: Experimental hematology & oncology
Published: May 26, 2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Journal: Leukemia & lymphoma
Published: January 08, 2015
Erysipeloid Hodgkin lymphoma.
Journal: European journal of dermatology : EJD
Published: August 15, 2014
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.
Journal: Blood cancer journal
Published: September 16, 2013
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Journal: American journal of hematology
Published: May 26, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026